These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Barrientos LG; O'Keefe BR; Bray M; Sanchez A; Gronenborn AM; Boyd MR Antiviral Res; 2003 Mar; 58(1):47-56. PubMed ID: 12719006 [TBL] [Abstract][Full Text] [Related]
3. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. Shenoy SR; O'Keefe BR; Bolmstedt AJ; Cartner LK; Boyd MR J Pharmacol Exp Ther; 2001 May; 297(2):704-10. PubMed ID: 11303061 [TBL] [Abstract][Full Text] [Related]
4. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592 [TBL] [Abstract][Full Text] [Related]
5. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Bolmstedt AJ; O'Keefe BR; Shenoy SR; McMahon JB; Boyd MR Mol Pharmacol; 2001 May; 59(5):949-54. PubMed ID: 11306674 [TBL] [Abstract][Full Text] [Related]
6. A Designed "Nested" Dimer of Cyanovirin-N Increases Antiviral Activity. Woodrum BW; Maxwell J; Allen DM; Wilson J; Krumpe LR; Bobkov AA; Hill RB; Kibler KV; O'Keefe BR; Ghirlanda G Viruses; 2016 Jun; 8(6):. PubMed ID: 27275831 [TBL] [Abstract][Full Text] [Related]
7. The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy. Barrientos LG; Gronenborn AM Mini Rev Med Chem; 2005 Jan; 5(1):21-31. PubMed ID: 15638789 [TBL] [Abstract][Full Text] [Related]
8. Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability. Maier I; Schiestl RH; Kontaxis G Molecules; 2021 Jun; 26(12):. PubMed ID: 34199200 [TBL] [Abstract][Full Text] [Related]
9. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930 [TBL] [Abstract][Full Text] [Related]
10. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. Helle F; Wychowski C; Vu-Dac N; Gustafson KR; Voisset C; Dubuisson J J Biol Chem; 2006 Sep; 281(35):25177-83. PubMed ID: 16809348 [TBL] [Abstract][Full Text] [Related]
11. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Smee DF; Bailey KW; Wong MH; O'Keefe BR; Gustafson KR; Mishin VP; Gubareva LV Antiviral Res; 2008 Dec; 80(3):266-71. PubMed ID: 18601954 [TBL] [Abstract][Full Text] [Related]
12. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. Balzarini J; Van Laethem K; Peumans WJ; Van Damme EJ; Bolmstedt A; Gago F; Schols D J Virol; 2006 Sep; 80(17):8411-21. PubMed ID: 16912292 [TBL] [Abstract][Full Text] [Related]
13. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334 [TBL] [Abstract][Full Text] [Related]
14. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition. Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344 [TBL] [Abstract][Full Text] [Related]
15. Ching-fang-pai-tu-san inhibits the release of influenza virus. Hsieh CF; Yen HR; Liu CH; Lin S; Horng JT J Ethnopharmacol; 2012 Dec; 144(3):533-44. PubMed ID: 23041224 [TBL] [Abstract][Full Text] [Related]
16. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Witvrouw M; De Clercq E Gen Pharmacol; 1997 Oct; 29(4):497-511. PubMed ID: 9352294 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. Kachko A; Loesgen S; Shahzad-Ul-Hussan S; Tan W; Zubkova I; Takeda K; Wells F; Rubin S; Bewley CA; Major ME Mol Pharm; 2013 Dec; 10(12):4590-4602. PubMed ID: 24152340 [TBL] [Abstract][Full Text] [Related]
18. Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides. Botos I; O'Keefe BR; Shenoy SR; Cartner LK; Ratner DM; Seeberger PH; Boyd MR; Wlodawer A J Biol Chem; 2002 Sep; 277(37):34336-42. PubMed ID: 12110688 [TBL] [Abstract][Full Text] [Related]
19. High throughput screening for cyanovirin-N mimetics binding to HIV-1 gp41. Beutler JA; McMahon JB; Johnson TR; O'Keefe BR; Buzzell RA; Robbins D; Gardella R; Wilson J; Boyd MR J Biomol Screen; 2002 Apr; 7(2):105-10. PubMed ID: 12006108 [TBL] [Abstract][Full Text] [Related]
20. Herbal Medicines with Antiviral Activity Against the Influenza Virus, a Systematic Review. Lee JY; Abundo MEC; Lee CW Am J Chin Med; 2018; 46(8):1663-1700. PubMed ID: 30612461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]